|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2005-9-7
|
|
pubmed:abstractText |
Clinical data indicate that estrogen receptor-positive/progesterone receptor-negative (ER+/PR-) breast cancers are less sensitive to tamoxifen than are ER+/PR+ tumors. It has also been reported that tamoxifen may be less effective in tumors that overexpress either HER-2 or HER-1 (epidermal growth factor receptor) and that signaling through these receptors reduces PR expression in experimental models. We hypothesized that ER+/PR- breast tumors are more likely than ER+/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
7
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1254-61
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16145046-Adult,
pubmed-meshheading:16145046-Aged,
pubmed-meshheading:16145046-Aged, 80 and over,
pubmed-meshheading:16145046-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16145046-Breast Neoplasms,
pubmed-meshheading:16145046-Chemotherapy, Adjuvant,
pubmed-meshheading:16145046-Confidence Intervals,
pubmed-meshheading:16145046-Disease-Free Survival,
pubmed-meshheading:16145046-Drug Resistance, Neoplasm,
pubmed-meshheading:16145046-Female,
pubmed-meshheading:16145046-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16145046-Humans,
pubmed-meshheading:16145046-Middle Aged,
pubmed-meshheading:16145046-Odds Ratio,
pubmed-meshheading:16145046-Proportional Hazards Models,
pubmed-meshheading:16145046-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16145046-Receptor, erbB-2,
pubmed-meshheading:16145046-Receptors, Estrogen,
pubmed-meshheading:16145046-Receptors, Progesterone,
pubmed-meshheading:16145046-Tamoxifen,
pubmed-meshheading:16145046-Treatment Outcome,
pubmed-meshheading:16145046-Tumor Markers, Biological,
pubmed-meshheading:16145046-Up-Regulation
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
|
|
pubmed:affiliation |
Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
